Global Non-opioid Pain Med market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Global Non-opioid Pain Med Market Size, Share and Analysis

The global Non-opioid Pain Med market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the Non-opioid Pain Med Industry Forecast looks at past sales and reviews total world Non-opioid Pain Med sales in 2024, providing a comprehensive analysis by region and market sector of projected Non-opioid Pain Med sales for 2025 through 2031. With Non-opioid Pain Med sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-opioid Pain Med industry. This Insight Report provides a comprehensive analysis of the global Non-opioid Pain Med landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Non-opioid Pain Med portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Non-opioid Pain Med market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-opioid Pain Med and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-opioid Pain Med. This report presents a comprehensive overview, market shares, and growth opportunities of Non-opioid Pain Med market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Diclofenac Sodium &nbsp;&nbsp;&nbsp; Acetaminophen &nbsp;&nbsp;&nbsp; Indomethacin &nbsp;&nbsp;&nbsp; Ibuprofen &nbsp;&nbsp;&nbsp; Aspirin &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Mild Pain &nbsp;&nbsp;&nbsp; Moderate Pain This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; WEX Pharmaceuticals Inc. &nbsp;&nbsp;&nbsp; BASF &nbsp;&nbsp;&nbsp; Xinhua Pharm &nbsp;&nbsp;&nbsp; Johnson & Johnson?McNeil Consumer Healthcare? &nbsp;&nbsp;&nbsp; Granules Biocause &nbsp;&nbsp;&nbsp; Novacyl &nbsp;&nbsp;&nbsp; Pfizer &nbsp;&nbsp;&nbsp; Hisoar &nbsp;&nbsp;&nbsp; Anant Pharmaceuticals Pvt. Ltd. &nbsp;&nbsp;&nbsp; Strides Shasun &nbsp;&nbsp;&nbsp; SI Group &nbsp;&nbsp;&nbsp; Elam Pharma &nbsp;&nbsp;&nbsp; AdvaCare Pharma &nbsp;&nbsp;&nbsp; IOL &nbsp;&nbsp;&nbsp; Jingye Group &nbsp;&nbsp;&nbsp; NS Chemicals &nbsp;&nbsp;&nbsp; Hunan Zhongnan Pharmaceutical &nbsp;&nbsp;&nbsp; Nanjing Pharmaceutical Factory &nbsp;&nbsp;&nbsp; Huayin Jinqiancheng Pharmaceutical Co., Ltd. &nbsp;&nbsp;&nbsp; Mallinckrodt Pharmaceuticals Key Questions Addressed in this Report What is the 10-year outlook for the global Non-opioid Pain Med market? What factors are driving Non-opioid Pain Med market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Non-opioid Pain Med market opportunities vary by end market size? How does Non-opioid Pain Med break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Non-opioid Pain Med Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Non-opioid Pain Med by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Non-opioid Pain Med by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Non-opioid Pain Med Segment by Type &nbsp;2.2.1 Diclofenac Sodium &nbsp;2.2.2 Acetaminophen &nbsp;2.2.3 Indomethacin &nbsp;2.2.4 Ibuprofen &nbsp;2.2.5 Aspirin &nbsp;2.2.6 Others &nbsp;2.3 Non-opioid Pain Med Sales by Type &nbsp;2.3.1 Global Non-opioid Pain Med Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Non-opioid Pain Med Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Non-opioid Pain Med Sale Price by Type (2020-2025) &nbsp;2.4 Non-opioid Pain Med Segment by Application &nbsp;2.4.1 Mild Pain &nbsp;2.4.2 Moderate Pain &nbsp;2.5 Non-opioid Pain Med Sales by Application &nbsp;2.5.1 Global Non-opioid Pain Med Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Non-opioid Pain Med Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Non-opioid Pain Med Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Non-opioid Pain Med Breakdown Data by Company &nbsp;3.1.1 Global Non-opioid Pain Med Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Non-opioid Pain Med Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Non-opioid Pain Med Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Non-opioid Pain Med Revenue by Company (2020-2025) &nbsp;3.2.2 Global Non-opioid Pain Med Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Non-opioid Pain Med Sale Price by Company &nbsp;3.4 Key Manufacturers Non-opioid Pain Med Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Non-opioid Pain Med Product Location Distribution &nbsp;3.4.2 Players Non-opioid Pain Med Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Non-opioid Pain Med by Geographic Region &nbsp;4.1 World Historic Non-opioid Pain Med Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Non-opioid Pain Med Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Non-opioid Pain Med Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Non-opioid Pain Med Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Non-opioid Pain Med Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Non-opioid Pain Med Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Non-opioid Pain Med Sales Growth &nbsp;4.4 APAC Non-opioid Pain Med Sales Growth &nbsp;4.5 Europe Non-opioid Pain Med Sales Growth &nbsp;4.6 Middle East & Africa Non-opioid Pain Med Sales Growth 5 Americas &nbsp;5.1 Americas Non-opioid Pain Med Sales by Country &nbsp;5.1.1 Americas Non-opioid Pain Med Sales by Country (2020-2025) &nbsp;5.1.2 Americas Non-opioid Pain Med Revenue by Country (2020-2025) &nbsp;5.2 Americas Non-opioid Pain Med Sales by Type (2020-2025) &nbsp;5.3 Americas Non-opioid Pain Med Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Non-opioid Pain Med Sales by Region &nbsp;6.1.1 APAC Non-opioid Pain Med Sales by Region (2020-2025) &nbsp;6.1.2 APAC Non-opioid Pain Med Revenue by Region (2020-2025) &nbsp;6.2 APAC Non-opioid Pain Med Sales by Type (2020-2025) &nbsp;6.3 APAC Non-opioid Pain Med Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Non-opioid Pain Med by Country &nbsp;7.1.1 Europe Non-opioid Pain Med Sales by Country (2020-2025) &nbsp;7.1.2 Europe Non-opioid Pain Med Revenue by Country (2020-2025) &nbsp;7.2 Europe Non-opioid Pain Med Sales by Type (2020-2025) &nbsp;7.3 Europe Non-opioid Pain Med Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Non-opioid Pain Med by Country &nbsp;8.1.1 Middle East & Africa Non-opioid Pain Med Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Non-opioid Pain Med Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Non-opioid Pain Med Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Non-opioid Pain Med Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Non-opioid Pain Med &nbsp;10.3 Manufacturing Process Analysis of Non-opioid Pain Med &nbsp;10.4 Industry Chain Structure of Non-opioid Pain Med 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Non-opioid Pain Med Distributors &nbsp;11.3 Non-opioid Pain Med Customer 12 World Forecast Review for Non-opioid Pain Med by Geographic Region &nbsp;12.1 Global Non-opioid Pain Med Market Size Forecast by Region &nbsp;12.1.1 Global Non-opioid Pain Med Forecast by Region (2026-2031) &nbsp;12.1.2 Global Non-opioid Pain Med Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Non-opioid Pain Med Forecast by Type (2026-2031) &nbsp;12.7 Global Non-opioid Pain Med Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 WEX Pharmaceuticals Inc. &nbsp;13.1.1 WEX Pharmaceuticals Inc. Company Information &nbsp;13.1.2 WEX Pharmaceuticals Inc. Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.1.3 WEX Pharmaceuticals Inc. Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 WEX Pharmaceuticals Inc. Main Business Overview &nbsp;13.1.5 WEX Pharmaceuticals Inc. Latest Developments &nbsp;13.2 BASF &nbsp;13.2.1 BASF Company Information &nbsp;13.2.2 BASF Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.2.3 BASF Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 BASF Main Business Overview &nbsp;13.2.5 BASF Latest Developments &nbsp;13.3 Xinhua Pharm &nbsp;13.3.1 Xinhua Pharm Company Information &nbsp;13.3.2 Xinhua Pharm Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.3.3 Xinhua Pharm Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Xinhua Pharm Main Business Overview &nbsp;13.3.5 Xinhua Pharm Latest Developments &nbsp;13.4 Johnson & Johnson?McNeil Consumer Healthcare? &nbsp;13.4.1 Johnson & Johnson?McNeil Consumer Healthcare? Company Information &nbsp;13.4.2 Johnson & Johnson?McNeil Consumer Healthcare? Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.4.3 Johnson & Johnson?McNeil Consumer Healthcare? Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Johnson & Johnson?McNeil Consumer Healthcare? Main Business Overview &nbsp;13.4.5 Johnson & Johnson?McNeil Consumer Healthcare? Latest Developments &nbsp;13.5 Granules Biocause &nbsp;13.5.1 Granules Biocause Company Information &nbsp;13.5.2 Granules Biocause Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.5.3 Granules Biocause Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Granules Biocause Main Business Overview &nbsp;13.5.5 Granules Biocause Latest Developments &nbsp;13.6 Novacyl &nbsp;13.6.1 Novacyl Company Information &nbsp;13.6.2 Novacyl Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.6.3 Novacyl Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Novacyl Main Business Overview &nbsp;13.6.5 Novacyl Latest Developments &nbsp;13.7 Pfizer &nbsp;13.7.1 Pfizer Company Information &nbsp;13.7.2 Pfizer Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.7.3 Pfizer Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Pfizer Main Business Overview &nbsp;13.7.5 Pfizer Latest Developments &nbsp;13.8 Hisoar &nbsp;13.8.1 Hisoar Company Information &nbsp;13.8.2 Hisoar Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.8.3 Hisoar Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Hisoar Main Business Overview &nbsp;13.8.5 Hisoar Latest Developments &nbsp;13.9 Anant Pharmaceuticals Pvt. Ltd. &nbsp;13.9.1 Anant Pharmaceuticals Pvt. Ltd. Company Information &nbsp;13.9.2 Anant Pharmaceuticals Pvt. Ltd. Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.9.3 Anant Pharmaceuticals Pvt. Ltd. Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Anant Pharmaceuticals Pvt. Ltd. Main Business Overview &nbsp;13.9.5 Anant Pharmaceuticals Pvt. Ltd. Latest Developments &nbsp;13.10 Strides Shasun &nbsp;13.10.1 Strides Shasun Company Information &nbsp;13.10.2 Strides Shasun Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.10.3 Strides Shasun Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Strides Shasun Main Business Overview &nbsp;13.10.5 Strides Shasun Latest Developments &nbsp;13.11 SI Group &nbsp;13.11.1 SI Group Company Information &nbsp;13.11.2 SI Group Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.11.3 SI Group Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 SI Group Main Business Overview &nbsp;13.11.5 SI Group Latest Developments &nbsp;13.12 Elam Pharma &nbsp;13.12.1 Elam Pharma Company Information &nbsp;13.12.2 Elam Pharma Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.12.3 Elam Pharma Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 Elam Pharma Main Business Overview &nbsp;13.12.5 Elam Pharma Latest Developments &nbsp;13.13 AdvaCare Pharma &nbsp;13.13.1 AdvaCare Pharma Company Information &nbsp;13.13.2 AdvaCare Pharma Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.13.3 AdvaCare Pharma Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 AdvaCare Pharma Main Business Overview &nbsp;13.13.5 AdvaCare Pharma Latest Developments &nbsp;13.14 IOL &nbsp;13.14.1 IOL Company Information &nbsp;13.14.2 IOL Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.14.3 IOL Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.14.4 IOL Main Business Overview &nbsp;13.14.5 IOL Latest Developments &nbsp;13.15 Jingye Group &nbsp;13.15.1 Jingye Group Company Information &nbsp;13.15.2 Jingye Group Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.15.3 Jingye Group Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.15.4 Jingye Group Main Business Overview &nbsp;13.15.5 Jingye Group Latest Developments &nbsp;13.16 NS Chemicals &nbsp;13.16.1 NS Chemicals Company Information &nbsp;13.16.2 NS Chemicals Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.16.3 NS Chemicals Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.16.4 NS Chemicals Main Business Overview &nbsp;13.16.5 NS Chemicals Latest Developments &nbsp;13.17 Hunan Zhongnan Pharmaceutical &nbsp;13.17.1 Hunan Zhongnan Pharmaceutical Company Information &nbsp;13.17.2 Hunan Zhongnan Pharmaceutical Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.17.3 Hunan Zhongnan Pharmaceutical Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.17.4 Hunan Zhongnan Pharmaceutical Main Business Overview &nbsp;13.17.5 Hunan Zhongnan Pharmaceutical Latest Developments &nbsp;13.18 Nanjing Pharmaceutical Factory &nbsp;13.18.1 Nanjing Pharmaceutical Factory Company Information &nbsp;13.18.2 Nanjing Pharmaceutical Factory Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.18.3 Nanjing Pharmaceutical Factory Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.18.4 Nanjing Pharmaceutical Factory Main Business Overview &nbsp;13.18.5 Nanjing Pharmaceutical Factory Latest Developments &nbsp;13.19 Huayin Jinqiancheng Pharmaceutical Co., Ltd. &nbsp;13.19.1 Huayin Jinqiancheng Pharmaceutical Co., Ltd. Company Information &nbsp;13.19.2 Huayin Jinqiancheng Pharmaceutical Co., Ltd. Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.19.3 Huayin Jinqiancheng Pharmaceutical Co., Ltd. Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.19.4 Huayin Jinqiancheng Pharmaceutical Co., Ltd. Main Business Overview &nbsp;13.19.5 Huayin Jinqiancheng Pharmaceutical Co., Ltd. Latest Developments &nbsp;13.20 Mallinckrodt Pharmaceuticals &nbsp;13.20.1 Mallinckrodt Pharmaceuticals Company Information &nbsp;13.20.2 Mallinckrodt Pharmaceuticals Non-opioid Pain Med Product Portfolios and Specifications &nbsp;13.20.3 Mallinckrodt Pharmaceuticals Non-opioid Pain Med Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.20.4 Mallinckrodt Pharmaceuticals Main Business Overview &nbsp;13.20.5 Mallinckrodt Pharmaceuticals Latest Developments 14 Research Findings and Conclusion

Report	Global Non-opioid Pain Med Market Growth, Trends and Opportunities 2025-31
Selected License	Multi ID: LPI49860

Buyer Information

Order Summary